Thrombosis Research 2008-01-01

Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): in vitro effects on platelets.

Judi Bryant, Joseph M Post, Serene Alexander, Yi-Xin Wang, Lorraine Kent, Sabine Schirm, Jih-Lie Tseng, Babu Subramanyam, Brad Buckman, Imadul Islam, Shendong Yuan, Mark E Sullivan, Mike Snider, John Morser, Judi Bryant, Joseph M. Post, Serene Alexander, Yi-Xin Wang, Lorraine Kent, Sabine Schirm, Jih-Lie Tseng, Babu Subramanyam, Brad Buckman, Imadul Islam, Shendong Yuan, Mark E. Sullivan, Mike Snider, John Morser

Index: Thromb. Res. 122 , 523-32, (2008)

Full Text: HTML

Abstract

ADP plays a key role in platelet aggregation which has led to the development of antiplatelet drugs that target the P2Y12 receptor. The aim of this study was to characterize the effects of two novel P2Y12 receptor antagonists, BX 667 and its active metabolite BX 048, on platelets. BX 667 and BX 048 block the binding of 2MeSADP to platelets and antagonize ADP-induced platelet aggregation in human, dog and rat washed platelets. Both compounds were shown to be reversible inhibitors of platelet aggregation. BX 048 prevents the decrease in cAMP induced by treatment of platelets with ADP. The specificity of BX 667 and BX 048 was demonstrated against cell lines expressing P2Y1 and P2Y6 as well as against a panel of receptors and enzymes. Taken all together these data show that both BX 048 and BX 667 are potent P2Y12 antagonists with high specificity which, in the accompanying paper are demonstrated to behave predictably in vivo.